{"id":69085,"date":"2026-06-30T12:01:00","date_gmt":"2026-06-30T04:01:00","guid":{"rendered":"https:\/\/flcube.com\/?p=69085"},"modified":"2026-06-30T12:01:01","modified_gmt":"2026-06-30T04:01:01","slug":"abbvie-and-genmabs-epcoritamab-lenalidomide-combination-achieves-primary-endpoint-in-phase-3-dlbcl-trial-60-reduction-in-progression-death-risk-vs-standard-r-gemox","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69085","title":{"rendered":"AbbVie and Genmab&#8217;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced positive topline results from the <strong>Phase 3 EPCORE DLBCL-4 trial<\/strong>, demonstrating that the combination of <strong>epcoritamab<\/strong> and <strong>lenalidomide<\/strong> significantly improved <strong>progression-free survival (PFS)<\/strong> compared to standard <strong>rituximab plus gemcitabine plus oxaliplatin (R-GemOx)<\/strong> in adult patients with <strong>relapsed or refractory diffuse large B-cell lymphoma (DLBCL)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-summary\" class=\"wp-block-heading\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>U.S. Analysis<\/th><th>Ex-U.S. Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met (statistically significant PFS improvement)<\/td><td>Met (statistically significant PFS improvement)<\/td><\/tr><tr><td><strong>Hazard Ratio (HR)<\/strong><\/td><td>0.40<\/td><td>0.44<\/td><\/tr><tr><td><strong>95% Confidence Interval<\/strong><\/td><td>[0.30, 0.55]<\/td><td>[0.33, 0.60]<\/td><\/tr><tr><td><strong>Risk Reduction<\/strong><\/td><td>60%<\/td><td>56%<\/td><\/tr><tr><td><strong>p-value<\/strong><\/td><td>&lt;0.0001<\/td><td>&lt;0.0001<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>R\/R DLBCL with \u22651 prior therapy<\/td><td>R\/R DLBCL with \u22651 prior therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-epcoritamab\" class=\"wp-block-heading\">Drug Profile: Epcoritamab<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: T-cell engaging bispecific antibody targeting CD3 (T-cells) and CD20 (B-cells)<\/li>\n\n\n\n<li><strong>Technology Platform<\/strong>: Genmab&#8217;s proprietary DuoBody technology<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Subcutaneous delivery<\/li>\n\n\n\n<li><strong>Development Partnership<\/strong>: Co-developed by AbbVie and Genmab under oncology collaboration<\/li>\n\n\n\n<li><strong>Commercial Rights<\/strong>: Shared U.S. and Japan responsibilities; AbbVie handles global commercialization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Epcoritamab represents a novel immunotherapy approach that bridges cytotoxic T-cells with malignant B-cells, enabling targeted tumor cell killing while sparing healthy tissues. The subcutaneous administration offers significant patient convenience advantages over intravenous therapies commonly used in lymphoma treatment.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-significance\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>DLBCL Burden<\/strong><\/td><td>Most common form of non-Hodgkin lymphoma; ~25,000 new U.S. cases annually<\/td><\/tr><tr><td><strong>Treatment Gap<\/strong><\/td><td>Limited effective options for relapsed\/refractory patients after first-line failure<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>R-GemOx represents conventional chemotherapy-based salvage regimen<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Competes with CAR-T therapies and other bispecific antibodies in development<\/td><\/tr><tr><td><strong>Clinical Impact<\/strong><\/td><td>60% risk reduction represents substantial improvement over existing salvage options<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Relapsed or refractory DLBCL represents a critical unmet medical need, with median overall survival of less than 12 months for patients who fail first-line therapy. The EPCORE DLBCL-4 results suggest that epcoritamab-lenalidomide could become a new standard of care for this difficult-to-treat population, offering both superior efficacy and improved tolerability compared to intensive chemotherapy regimens.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity<\/strong>: Estimated $2 billion peak sales potential in R\/R DLBCL indication<\/li>\n\n\n\n<li><strong>Pricing Advantage<\/strong>: Subcutaneous bispecific likely priced below CAR-T therapies (~$400K vs ~$1M)<\/li>\n\n\n\n<li><strong>Accessibility<\/strong>: Outpatient administration expands treatment access beyond specialized CAR-T centers<\/li>\n\n\n\n<li><strong>Partnership Synergy<\/strong>: Leverages AbbVie&#8217;s commercial infrastructure and Genmab&#8217;s bispecific expertise<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Priority review likely given magnitude of clinical benefit<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The safety profile of the epcoritamab-lenalidomide combination was consistent with known profiles of individual agents, suggesting manageable toxicity without unexpected adverse events. This favorable risk-benefit profile positions the regimen as a viable alternative to more toxic chemotherapy approaches and expensive cellular therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory submissions, and commercial expectations for epcoritamab. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,17,29,368,28,853],"class_list":["post-69085","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbvie","tag-clinical-trial-results","tag-combination-therapy","tag-genmab","tag-multi-specific-antibodies","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie and Genmab&#039;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69085\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie and Genmab&#039;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69085\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T04:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-30T04:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie and Genmab&#8217;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\\\/Death Risk vs Standard R-GemOx\",\"datePublished\":\"2026-06-30T04:01:00+00:00\",\"dateModified\":\"2026-06-30T04:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085\"},\"wordCount\":452,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Clinical trial results\",\"Combination therapy\",\"Genmab\",\"Multi-specific antibodies\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69085#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69085\",\"name\":\"AbbVie and Genmab's Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\\\/Death Risk vs Standard R-GemOx - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-30T04:01:00+00:00\",\"dateModified\":\"2026-06-30T04:01:01+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69085\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69085#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie and Genmab&#8217;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\\\/Death Risk vs Standard R-GemOx\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie and Genmab's Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69085","og_locale":"en_US","og_type":"article","og_title":"AbbVie and Genmab's Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx","og_description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).","og_url":"https:\/\/flcube.com\/?p=69085","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T04:01:00+00:00","article_modified_time":"2026-06-30T04:01:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69085#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69085"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie and Genmab&#8217;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx","datePublished":"2026-06-30T04:01:00+00:00","dateModified":"2026-06-30T04:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69085"},"wordCount":452,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Clinical trial results","Combination therapy","Genmab","Multi-specific antibodies","NYSE: ABBV"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69085#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69085","url":"https:\/\/flcube.com\/?p=69085","name":"AbbVie and Genmab's Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-30T04:01:00+00:00","dateModified":"2026-06-30T04:01:01+00:00","description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of epcoritamab and lenalidomide significantly improved progression-free survival (PFS) compared to standard rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69085#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69085"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69085#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie and Genmab&#8217;s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial \u2013 60% Reduction in Progression\/Death Risk vs Standard R-GemOx"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69085"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69085\/revisions"}],"predecessor-version":[{"id":69088,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69085\/revisions\/69088"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}